Panelists discuss how policy makers can increase biosimilar adoption through financial incentives, streamlined interchangeability rules, and addressing patent litigation delays, emphasizing that biosimilar savings will ultimately help fund the next wave of health care innovation such as cell and gene therapies.
Policy Considerations and Future Directions
Key Themes:
Key Points for Physicians:
Notable Insights:
Implementing biosimilars represents an opportunity for health care organizations to demonstrate good stewardship of limited health care resources while maintaining quality care.
Clinical Significance: Policy interventions that streamline interchangeability, align stakeholder incentives, and address patent litigation delays can accelerate biosimilar adoption, ultimately enabling investment in next-generation therapies while maintaining sustainable health care costs.
FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older
July 29th 2025The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Read More